Physician profile
Howard Mitchell Goodman
NPI 1114926904
$4,963.36
in general payments reported to CMS, 2019-2025
62 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $369 · 2021: $410 · 2022: $896 · 2023: $826 · 2024: $586 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.18 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $381.09 | 2019-2025 | Lynparza, Enhertu |
| Seagen INC. | $345.61 | 2020-2023 | Adcetris, Tukysa |
| Janssen Biotech, INC. | $318.87 | 2022-2025 | Erleada, Talvey, Darzalex |
| Glaxosmithkline, LLC. | $251.63 | 2020-2022 | |
| Eisai INC. | $234.06 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $231.87 | 2019-2025 | Keytruda, Lynparza |
| Intuitive Surgical, INC. | $227.77 | 2021-2025 | |
| Lsi Solutions INC | $214.57 | 2023-2025 | Fornisee |
| Genentech USA, INC. | $185.28 | 2019-2025 | Phesgo, Rozlytrek, Tecentriq Hybreza |
| Bayer Healthcare Pharmaceuticals INC. | $158.85 | 2019-2025 | |
| Celgene Corporation | $157.78 | 2019-2024 | Reblozyl |
| Davol INC. | $148.32 | 2025 | Arista |
| Daiichi Sankyo INC. | $146.39 | 2020-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $128.74 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.60 | 2020-2025 | Ninlaro, Vonvendi |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.